The problem with immune checkpoint blockade is that it can turn your immune system into a tumor-hunting action hero, but only if the rest of the body lets it get through the door.
That “rest of the body” now very much includes your gut microbiota, the sprawling microbial metropolis living in your intestines. Yes, the same neighborhood involved in digesting lunch may also be quietly shaping whether cancer immunotherapy works. Biology looked at the phrase “gut feeling” and apparently took it personally.
In a 2026 review in Cell Metabolism, Joseph Gladstone and Gregory Sonnenberg pull together a fast-moving story: diet, gut microbes, microbial metabolites, and immune cells seem to form a communication loop that can influence responses to immune checkpoint blockade, or ICB, in cancer (Gladstone & Sonnenberg, 2026).
Checkpoints: The Immune System’s Badly Placed Brakes
Checkpoint inhibitors are cancer drugs that block signals like PD-1, PD-L1, or CTLA-4. Those signals normally help keep immune attacks under control, which is nice when your immune system is not supposed to redecorate your pancreas. But tumors can exploit these brakes to hide from T cells.
So checkpoint blockade says, basically: “Hey T cells, the suspicious lump over there? Maybe stop ignoring it.”
When this works, it can work dramatically. When it fails, it can fail with the emotional range of a printer jam. Some patients respond beautifully. Others do not. And one big question has been: why?
Part of the answer may be sitting in the gut, eating fiber and producing chemical text messages.
Your Microbes Are Tiny Chemists With Boundary Issues
Gut microbes do not just sit around being microscopic roommates. They metabolize food into compounds that can affect immunity locally in the gut and elsewhere in the body. Short-chain fatty acids such as acetate, propionate, and butyrate are classic examples, produced when microbes ferment dietary fiber. Other players include bile acid derivatives, tryptophan metabolites, inosine, and assorted molecular weirdness that sounds like it was named during a very long faculty meeting.
These metabolites can influence antigen presentation, T-cell activity, macrophage behavior, and inflammation. Translation: they may change how aggressively the immune system notices and attacks tumor cells.
The 2026 review emphasizes that this is not a simple “good bacteria equals good outcome” sticker you can slap on a yogurt cup. The same metabolite may help in one context and hurt in another, depending on dose, timing, tumor type, immune state, and probably several variables currently hiding behind the lab equipment.
Fiber, Probiotics, And The “Please Don’t DIY Your Cancer Care” Section
One reason this field got so much attention is that diet looks modifiable. In a 2021 Science study of melanoma patients receiving checkpoint blockade, higher dietary fiber intake was associated with better outcomes, while probiotic supplement use did not look automatically helpful and in some mouse models appeared to impair anti-PD-1 response (Spencer et al., 2021; PMCID: PMC8970537).
That does not mean fiber is magic confetti. It means the microbiome may be a lever, and food may be one way to move it. But the lever is attached to a complicated machine labeled “human immunology,” which is scientist for “please do not yank this randomly.”
Fecal microbiota transplantation, or FMT, has also been tested. In a small 2021 Science trial, researchers gave stool microbiota from immunotherapy responders to patients with melanoma whose disease had resisted anti-PD-1 therapy. Some patients showed clinical benefit when FMT was combined with anti-PD-1 retreatment (Davar et al., 2021; PMCID: PMC8097968). That is intriguing. It is also not a green light for backyard microbiome experiments, because no sentence involving cancer care and “backyard” should continue.
The Catch: Everyone’s Gut Is Annoyingly Personal
A major challenge is that no two microbiomes are exactly alike. Your microbial lineup depends on diet, antibiotics, geography, age, illness, medications, and probably that one week in college when dinner was mostly vending machine snacks. This makes it hard to define one universal “healthy” immunotherapy microbiome.
A 2023 Nature Reviews Clinical Oncology review made the same point: gut microbiota can shape antitumor immunity and treatment toxicity, but translating that into reliable clinical tools requires personalization (Simpson et al., 2023). A 2025 Journal of Experimental Medicine review similarly highlights microbiome-centered interventions, including diet, prebiotics, probiotics, synbiotics, and FMT, while stressing the need for better diagnostics and safety standards (Almonte et al., 2025; PMCID: PMC12013646).
So the future is probably not “eat this one superfood and defeat cancer,” because biology refuses to be that cooperative. More likely, clinicians may one day profile a patient’s tumor, immune system, stool microbiome, and metabolite patterns, then choose a tailored strategy to improve response or reduce toxicity.
Why This Review Matters
Gladstone and Sonnenberg’s review matters because it frames the gut as part of the cancer treatment ecosystem, not a digestive side character wandering through the plot. If researchers can map the diet-microbe-metabolite-immune loop more precisely, they may find ways to make checkpoint blockade work for more patients, predict who is likely to respond, and avoid interventions that sound healthy but backfire.
That is the real promise here: not replacing immunotherapy with kale, but learning how the body’s microbial chemistry might help immunotherapy do its job. The immune system may be the security team, but the gut microbes might be controlling the building access cards. Rude? Yes. Useful to know? Absolutely.
References
Gladstone JL, Sonnenberg GF. Gut microbiota and metabolic control of immune checkpoint blockade in cancer. Cell Metabolism. 2026. DOI: 10.1016/j.cmet.2026.04.018
Simpson RC, Shanahan ER, Scolyer RA, Long GV, et al. Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors. Nature Reviews Clinical Oncology. 2023;20:697-715. DOI: 10.1038/s41571-023-00803-9
Spencer CN, et al. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science. 2021;374:1632-1640. DOI: 10.1126/science.aaz7015. PMCID: PMC8970537
Davar D, et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science. 2021;371:595-602. DOI: 10.1126/science.abf3363. PMCID: PMC8097968
Almonte AA, Thomas S, Zitvogel L. Microbiota-centered interventions to boost immune checkpoint blockade therapies. Journal of Experimental Medicine. 2025;222:e20250378. DOI: 10.1084/jem.20250378. PMCID: PMC12013646
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.